GlyNAC: Glycine + NAC Protocol That Reverses Aging Markers

At a Glance

Glutathione is the body’s master antioxidant, synthesized in every cell from three amino acids: cysteine, glycine, and glutamate. By midlife, intracellular glutathione concentrations have declined by 50% or more compared to young adults. That single deficit cascades into mitochondrial dysfunction, accumulating oxidative damage, chronic low-grade inflammation, and the clinical frailty we associate with biological aging. For years, clinicians tried to correct this by supplementing glutathione directly—largely unsuccessfully, because oral glutathione is poorly absorbed and IV glutathione, while effective, does not durably raise intracellular levels. The breakthrough came when researchers asked a simpler question: why is synthesis impaired in the first place?

The answer, confirmed in a series of studies from Baylor College of Medicine, is substrate insufficiency. Older adults are deficient not in the enzyme that makes glutathione (glutathione synthetase) but in the raw materials it needs—specifically cysteine and glycine. Replenishing both simultaneously, as GlyNAC, reliably restores intracellular glutathione to youthful levels and, remarkably, reverses multiple downstream aging phenotypes.

Why Glutathione Declines With Age—and Why It Matters

Glutathione exists in two forms: reduced (GSH), which is the active antioxidant, and oxidized (GSSG). The ratio of GSH to GSSG is a real-time readout of cellular redox status. In healthy young cells, GSH predominates overwhelmingly. In older cells, GSSG accumulates, signaling a state of chronic oxidative stress.

The consequences are not merely biochemical abstractions. Elevated reactive oxygen species (ROS) directly damage mitochondrial DNA, impair electron transport chain function, and reduce ATP output. Cells that cannot meet their energy demands mount a compensatory inflammatory response—which is why mitochondrial dysfunction and systemic inflammation are so tightly correlated in aging tissue. Damaged mitochondria also leak cytochrome c, driving background apoptosis and contributing to the loss of muscle mass, cognitive tissue, and endothelial integrity that characterize the aging phenotype.

Glycine depletion compounds the problem independently. Beyond its role as a glutathione precursor, glycine is a major inhibitory neurotransmitter, a structural component of collagen, and a cofactor in heme synthesis. Plasma glycine levels decline measurably with age, and lower glycine is associated with metabolic syndrome, insulin resistance, and shorter lifespan in animal models. Cysteine, the other rate-limiting substrate, falls alongside glycine as dietary intake and endogenous synthesis both decrease. For a detailed review of glycine’s independent roles in sleep, collagen synthesis, and longevity signalling, see the glycine supplement guide.

The logic of GlyNAC is therefore direct: supply both missing precursors simultaneously. NAC (N-acetylcysteine) provides bioavailable cysteine; glycine is taken as the free amino acid.

The Baylor RCT: What 24 Weeks of GlyNAC Actually Did

The pivotal evidence comes from a double-blind, placebo-controlled, randomized trial published in the Journal of Nutrition (Kumar et al., 2023). Forty-two older adults (mean age 71) were randomized to GlyNAC or placebo for 24 weeks. The results were striking enough to prompt a Nature Aging editorial calling GlyNAC “one of the most comprehensive anti-aging interventions tested in humans to date.”

Metabolic and Cellular Outcomes

• Glutathione deficit corrected: Red blood cell GSH rose to levels indistinguishable from young controls (mean age 24) by week 24. GSSG ratios normalized in parallel.
• Oxidative stress reduced: Plasma F2-isoprostanes (a validated oxidative stress biomarker) decreased 66% versus placebo.
• Mitochondrial function restored: Muscle biopsies showed normalization of mitochondrial membrane potential and electron transport chain efficiency. ATP production rates increased significantly.
• Inflammation lowered: IL-6, TNF-α, and hsCRP all decreased significantly in the GlyNAC group.
• Endothelial dysfunction improved: Flow-mediated dilation improved, consistent with lower vascular oxidative stress.
• Insulin resistance reduced: HOMA-IR improved; glucose disposal rates approached those of younger controls.

Physical and Functional Outcomes

What distinguished this trial from typical biomarker studies was measurement of functional endpoints:

• Muscle strength (grip strength) improved significantly
• Gait speed increased (a validated predictor of mortality in older adults)
• Exercise capacity improved as measured by 6-minute walk test
• Body composition: lean muscle mass increased while adipose tissue decreased

Cognitive Outcomes

A sub-study using standard cognitive testing batteries showed significant improvement in executive function, attention, and processing speed. The investigators attributed this to restored cerebral mitochondrial function and reduced neuroinflammation, consistent with the known role of oxidative stress in cognitive aging.

All improvements were sustained at 24 weeks and regressed toward baseline after supplementation stopped—confirming that GlyNAC requires continued use, not a one-time correction.

Mechanisms Beyond Glutathione Repletion

The breadth of GlyNAC’s effects suggests mechanisms beyond simple antioxidant top-up.

mTOR pathway modulation: Glycine has been shown to partially inhibit mTORC1 signaling, mimicking some of the downstream effects of caloric restriction. Lower mTOR activity promotes autophagy—cellular self-cleaning—which is one of the most robustly conserved longevity mechanisms across species.

Mitophagy induction: Restored mitochondrial membrane potential allows dysfunctional mitochondria to be recognized and cleared by mitophagy. This quality-control process slows as GSH declines and oxidative burden rises; GlyNAC restores the cellular energy gradient required to drive it.

NRF2 activation: NAC is a well-characterized activator of NRF2, the master transcription factor governing antioxidant gene expression. NRF2 upregulation induces heme oxygenase-1, glutathione peroxidase, superoxide dismutase, and thioredoxin reductase—creating a systemic antioxidant response that extends well beyond glutathione itself.

Collagen and connective tissue support: Glycine constitutes roughly one-third of all amino acids in collagen. GlyNAC supplementation provides substrate for both intracellular (GSH) and extracellular (collagen) glycine-dependent processes simultaneously, which may explain observations of improved skin elasticity and joint comfort in clinical users. For complementary coverage of the glycation axis — reactive carbonyl species and AGE formation that accumulate alongside oxidative stress — carnosine provides a distinct quenching mechanism worth stacking for comprehensive anti-aging support.

Dosing Protocol: How I Approach GlyNAC in Practice

The Baylor studies used weight-based dosing:

• Glycine: 1.33 mmol/kg/day ≈ 100 mg/kg/day
• NAC: 0.81 mmol/kg/day ≈ 66 mg/kg/day (as acetylcysteine, not anhydrous)

For a 70 kg adult, this translates to approximately 7 g glycine and 4.6 g NAC per day, typically split into two doses (morning and evening with food).

In practice, I often begin patients at 50% of target dose for the first two weeks to assess NAC tolerance—nausea is the most common adverse effect and is dose-dependent. Patients with a history of sulfa sensitivity or active kidney stones should be evaluated before starting NAC at these doses. Those on nitroglycerin should be counseled about the theoretical potentiation of vasodilation.

Timing considerations: Both compounds can be taken with or without food, though NAC nausea is reduced when taken with a meal. Glycine before sleep has independent evidence for improving slow-wave sleep quality (via core body temperature reduction), which provides an additional incentive for an evening dose.

Product sourcing: Bulk glycine powder is inexpensive and well-tolerated. NAC is widely available in 600 mg capsules; higher doses require multiple capsules or pharmaceutical-grade powder. Preformulated GlyNAC combination products exist but are generally more expensive than sourcing the components separately.

Duration: The Baylor trial ran 24 weeks with sustained effects. Based on the regression data after stopping, I recommend indefinite continuation in patients whose clinical picture warrants it—as one would with any longevity supplement.

Who Benefits Most From GlyNAC?

Not every patient needs GlyNAC, but certain presentations consistently prompt me to include it:

Chronic fatigue and mitochondrial complaints: Patients describing progressive fatigue, cognitive slowing, and post-exertional malaise often have measurable mitochondrial dysfunction. GlyNAC addresses upstream oxidative drivers rather than masking symptoms.

Long COVID and post-infectious states: Oxidative stress, mitochondrial injury, and glutathione depletion are consistent findings in post-COVID syndrome. GlyNAC appears in several ongoing clinical trials for this indication, and I have found it clinically useful as a component of post-COVID recovery protocols.

Metabolic syndrome and insulin resistance: The HOMA-IR improvements in the Baylor trial are clinically meaningful. Patients with elevated fasting glucose, visceral adiposity, and dyslipidemia who have not responded fully to lifestyle changes are reasonable candidates.

Chronic infection burden: Persistent infections—including Lyme disease and reactivated viruses—impose continuous oxidative stress that depletes glutathione. GlyNAC provides substrate support without interfering with antimicrobial treatments.

General longevity optimization: For patients in their 50s and 60s pursuing a comprehensive anti-aging protocol, GlyNAC offers a well-documented, low-cost intervention with broad functional endpoints. It pairs well with NAD+ precursors (addressing a complementary energy pathway) and senolytics (addressing a distinct aging hallmark).

GlyNAC vs. Direct Glutathione Supplementation

A frequent patient question is whether they can simply take glutathione instead. The answer is nuanced.

Oral glutathione: Absorption has improved with liposomal and S-acetyl formulations, and some studies show modest increases in blood glutathione. However, intracellular uptake—where it matters—remains suboptimal. Cells prefer to synthesize glutathione from precursors rather than import the intact tripeptide.

IV glutathione: Raises intracellular GSH acutely and reliably but requires repeated clinical administration, is significantly more expensive, and does not address the underlying substrate deficiency. I use IV glutathione for rapid antioxidant support (e.g., post-chelation, acute neuroinflammation) but GlyNAC for sustained repletion.

GlyNAC: Restores synthesis capacity rather than temporarily supplementing the end product. The Baylor data show normalization to youthful levels—a benchmark no oral or IV glutathione study has achieved comparably.

The clinical decision usually comes down to acuity: IV glutathione for rapid, short-term needs; GlyNAC for durable, cost-effective, long-term restoration.

Practical Integration With Other Longevity Protocols

GlyNAC does not meaningfully interact with most longevity supplements. A few integrative considerations:

• With NAD+ precursors (NMN/NR): Complementary rather than redundant. NAD+ primarily addresses sirtuin activation and PARP repair; GlyNAC addresses mitochondrial oxidative load. Together they address two distinct nodes of mitochondrial aging.
• With metformin: No pharmacokinetic interaction. Some clinicians prefer GlyNAC over metformin for patients whose primary concern is longevity rather than metabolic disease, given GlyNAC’s superior evidence for functional endpoints.
• With rapamycin: Additive logic—rapamycin inhibits mTOR while GlyNAC provides the substrate support to capitalize on enhanced autophagy.
• With chelation: NAC modestly promotes heavy metal mobilization via thiol binding. During active chelation protocols, I typically maintain GlyNAC as a repletion strategy rather than discontinuing it.

Related Articles

• NAC: Mechanisms, Dosing, and Clinical Uses
• Hallmarks of Aging: The Framework Behind Modern Longevity Medicine
• Senolytics: Clearing Zombie Cells to Slow Aging
• Mitochondria and Energy: Why Cellular Power Plants Drive Longevity
• Post-COVID Recovery Protocol

References

1. Kumar P, Liu C, Suliburk J, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks. J Nutr. 2023;153(4):1073–1085. PMID 36931699

2. Kumar P, Liu C, Suliburk JW, et al. Glycine and N-Acetylcysteine (GlyNAC) Supplementation in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Insulin Resistance, Endothelial Dysfunction, Genotoxicity, Muscle Strength, and Cognition. Clin Transl Med. 2021;11(3):e372. PMID 33783984

3. Sekhar RV. GlyNAC Supplementation Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Aging Hallmarks, Metabolic Defects, Muscle Strength, Cognitive Decline, and Body Composition in Older Adults. J Nutr. 2021;151(10):2796–2798. PMID 34378010

4. Kumar P, Osahon OW, Sekhar RV. GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage. Nutrients. 2022;14(5):1114. PMID 35268089

5. Coles LD, Tuite PJ, Öz G, et al. Repeated-Dose Oral N-Acetylcysteine in Parkinson’s Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress. J Clin Pharmacol. 2018;58(2):158–167. PMID 28892558

6. Razak MA, Begum PS, Viswanath B, Rajagopal S. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxid Med Cell Longev. 2017;2017:1716701. PMID 28337245

7. Teskey G, Abrahem R, Cao R, et al. Glutathione as a Marker for Human Disease. Adv Clin Chem. 2018;87:141–159. PMID 30342710